Elranatamab
- Generic Name
- Elranatamab
- Brand Names
- Elrexfio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2408850-14-4
- Unique Ingredient Identifier
- L0HR9A577V
- Background
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific antibody is c...
- Indication
Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
...
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
MagnetisMM-20: Priming Myeloma Tumor Cells for the Bispecific Bout
The 66th ASH Annual Meeting featured MagnetisMM-20, a phase 1b trial evaluating elranatamab (BCMA/CD3 bispecific antibody) in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma. Results showed 100% unconfirmed ORR, with no dose-limiting toxicities and common AEs including fatigue and infections. The priming dose strategy worked as anticipated, and the regimen showed promise for deep and long-lasting remissions, even in high-stage patients.
Dozens of Presentations Advance Multiple Myeloma Research at the American Society for ...
At the 2024 American Society of Hematology meeting, Dr. C. Ola Landgren and colleagues presented research on multiple myeloma, focusing on combination therapies, overcoming resistance, and precision medicine to improve patient outcomes and potentially cure the disease.
Immunotherapy Evolution Continues with Innovative Approaches to Multiple Myeloma Treatment
Immunomodulatory agents, monoclonal antibodies, bispecific antibodies, and CAR T-cell therapy have transformed multiple myeloma treatment. Despite improvements, MM remains incurable, prompting research into protein degradation and immune system activation. The triSpecific antibody JNJ-79635322 targets BCMA, GPRC5D, and CD3, showing promise in preclinical trials. Other approaches include BCMA-targeting ADCs like belantamab mafodotin and small molecule E3 ligase modulators like mezigdomide, aiming to enhance immunotherapies and prolong patient survival.
Related Clinical Trials:
Global Bispecific Antibodies Clinical Trials Market Size
Bispecific antibodies market highlights include >30 development platforms, >USD 8B market size in 2023, and >800 clinical trials. Key approved antibodies like Blincyto and Hemlibra have seen significant sales. The market is driven by innovations in immuno-oncology, with ongoing trials by major pharma companies and research institutions globally.
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed
Multiple studies report on survival outcomes and therapies for multiple myeloma, including retrospective analyses, phase trials, and real-world data, highlighting advancements in treatment strategies and overall survival improvements.
Man with incurable cancer among first to undergo ground-breaking new treatment
NHS approves groundbreaking myeloma drugs elranatamab and teclistamab for patients who have received three or more treatments. These bispecific antibodies, the first new class of myeloma drugs in nearly seven years in Scotland, can halt the disease for at least 11 months and induce complete remission in some previously non-responders.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath